TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16750450

Group type: EXPERIMENTAL
Intervention: Oxymorphone ER 10 mg q12h
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Oxymorphone ER 40 mg q12h
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Oxymorphone ER 50 mg q12h
Number of subjects: 370

Group type: COMPARATOR
Intervention: Placebo q12h
Number of subjects: 370
Study: 15233837

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 11505046

Group type: EXPERIMENTAL
Intervention: Active tryptophan depletion (concentrated amino acid drink with no tryptophan supplementation)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo depletion (similar drink containing tryptophan)
Number of subjects: 16
Study: 9241548

Group type: EXPERIMENTAL
Intervention: Various urological irrigating fluids (1,000 ml intravenous infusions)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Various urological irrigating fluids
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Dilutional hypocalcaemia
Number of subjects: 17
Study: 8501720

Group type: EXPERIMENTAL
Intervention: Subzonal insemination (n = 31 oocytes)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Subzonal insemination (n = 33 oocytes in second series)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Subzonal insemination (n = 11 embryo transfers)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Routine IVF (n = 23 oocytes)
Number of subjects: 5
Study: 3521258

Group type: EXPERIMENTAL
Intervention: Rimantadine hydrochloride
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 29297732

Group type: EXPERIMENTAL
Intervention: Canagliflozin (100 mg or 300 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Canagliflozin (100 mg with possible increase to 300 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27300645

Group type: EXPERIMENTAL
Intervention: ONO-9054 30 μg/mL
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: ONO-9054 10 μg/mL
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: ONO-9054 3 μg/mL
Number of subjects: 21
Study: 24806568

Group type: EXPERIMENTAL
Intervention: Internet-based intervention
Number of subjects: 210
Study: 22382793

Group type: EXPERIMENTAL
Intervention: 1% buffered lidocaine
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 256

Group type: COMPARATOR
Intervention: bacteriostatic normal saline
Number of subjects: 256
Study: 19781865

Group type: EXPERIMENTAL
Intervention: Modafinil (200mg, PO)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 19079958

Group type: EXPERIMENTAL
Intervention: HP-HMG (Menopur)
Number of subjects: 0

Group type: COMPARATOR
Intervention: rFSH (Gonal-F)
Number of subjects: 0
Study: 15825071

Group type: COMPARATOR
Intervention: Propranolol (titrated to reducing resting pulse by > or =25%)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Banding (performed monthly until varices were eradicated)
Number of subjects: 62
Study: 12425138

Group type: EXPERIMENTAL
Intervention: Ultrasound Tonsillectomy (TEuc‐group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional Tonsillectomy (TEkonv‐group)
Number of subjects: 50
Study: 10369190

Group type: EXPERIMENTAL
Intervention: Prednisone or prednisolone at 60 mg/m2 per day (up to 80 mg/day) for four to six weeks, followed by 40 mg/m2 every other day for another four to six weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prednisone at 60 mg/m2/day (up to 80 mg/day) until urine is protein free for three days, then 40 mg/m2 every other day for another month
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alkylating agent for eight weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term, alternate-day corticosteroid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide for 8 or 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 0
Study: 7729019

Group type: EXPERIMENTAL
Intervention: Surgical group (CABG surgery)
Number of subjects: 912

Group type: COMPARATOR
Intervention: Medical group (nonsurgical therapy)
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Randomized trial participants (CABG surgery)
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Randomizable patients (CABG surgery)
Number of subjects: 912
Study: 2045533

Group type: EXPERIMENTAL
Intervention: Ciprostene (120 ng/kg/min in 8-hour daily infusions for 7 days)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Ciprostene
Number of subjects: 211

Group type: COMPARATOR
Intervention: Ciprostene and Placebo
Number of subjects: 211
Study: 7426351

Group type: EXPERIMENTAL
Intervention: Influenza virus RIT 4050 (H3N2) vaccine
Number of subjects: 0
Study: 31135498

Group type: EXPERIMENTAL
Intervention: Best performing icon alarms
Number of subjects: 123

Group type: COMPARATOR
Intervention: Worst performing icon alarms
Number of subjects: 123
Study: 28705786

Group type: EXPERIMENTAL
Intervention: Synbiotic treatment (Lactobacillus casei, L. rhamnosus, L. plantarum, Bifidobacterium lactis, and prebiotics)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 25810595

Group type: EXPERIMENTAL
Intervention: Nanocrystalline hydroxyapatite (NcHA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nanocrystalline hydroxyapatite (NcHA) with platelet-rich fibrin (PRF)
Number of subjects: 20
Study: 23461638

Group type: EXPERIMENTAL
Intervention: GA + TEA (General Anesthesia + Thoracic Epidural Anesthesia)
Number of subjects: 40

Group type: COMPARATOR
Intervention: GA (General Anesthesia)
Number of subjects: 40
Study: 21563871

Group type: EXPERIMENTAL
Intervention: Milk supplemented with 5 ppm fluoride and probiotic bacteria (Lactobacillus rhamnosus LB21, 10^7 CFU/mL)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Milk with only probiotic bacteria
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Milk containing only fluoride
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard milk (placebo)
Number of subjects: 160
Study: 19731357

Group type: EXPERIMENTAL
Intervention: Partner-assisted emotional disclosure
Number of subjects: 130

Group type: COMPARATOR
Intervention: Couples cancer education/support intervention
Number of subjects: 130
Study: 17876280

Group type: EXPERIMENTAL
Intervention: Lamivudine combined with HBIg
Number of subjects: 29

Group type: COMPARATOR
Intervention: Lamivudine alone
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups (HBIg + Lamivudine and Lamivudine alone)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Patients adhering to long-term prophylaxis with lamivudine after early withdrawal of HBIg
Number of subjects: 29
Study: 15234485

Group type: EXPERIMENTAL
Intervention: Dynamic Flex foot
Number of subjects: 11

Group type: COMPARATOR
Intervention: Conventional SAFE foot
Number of subjects: 11
Study: 11731649

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (5 mg as sulfate)
Number of subjects: 1154

Group type: COMPARATOR
Intervention: Calcium, phosphorus, folate, and iron supplementation
Number of subjects: 1154
Study: 9205759

Group type: EXPERIMENTAL
Intervention: Ebrotidine 150 mg b.i.d
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ebrotidine 300 mg b.i.d
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ebrotidine 500 mg b.i.d
Number of subjects: 8
Study: 7991739

Group type: EXPERIMENTAL
Intervention: Family interventions
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 350
Study: 3068401

Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Inosine
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 102
Study: 31862830

Group type: EXPERIMENTAL
Intervention: Surgery and adjuvant middle meningeal artery embolization (ST+MMAE group)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Surgical treatment alone (ST group)
Number of subjects: 46
Study: 29526457

Group type: EXPERIMENTAL
Intervention: Minocycline (200mg per day)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 27129176

Group type: EXPERIMENTAL
Intervention: Thalidomide plus CHOP (T-CHOP)
Number of subjects: 65

Group type: COMPARATOR
Intervention: CHOP alone
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Thalidomide plus CHOP (T-CHOP) in Bcl-2 positive and Bcl-6 negative patients
Number of subjects: 65

Group type: COMPARATOR
Intervention: CHOP alone in Bcl-2 positive and Bcl-6 negative patients
Number of subjects: 65
Study: 25706883

Group type: EXPERIMENTAL
Intervention: Zegerid (20 mg)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Losec (20 mg)
Number of subjects: 239
Study: 24081841

Group type: EXPERIMENTAL
Intervention: Suture length to wound length ratio (SL:WL) of more than 4 with small tissue bites and short stitch intervals at Sundsvall Hospital (SH)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Suture length to wound length ratio (SL:WL) of more than 4 with small tissue bites and short stitch intervals at Erasmus University Medical Center (EMC)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Closure time at Sundsvall Hospital (SH)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Closure time at Erasmus University Medical Center (EMC)
Number of subjects: 36
Study: 20516439

Group type: EXPERIMENTAL
Intervention: MP-T (melphalan plus prednisone plus thalidomide 200 mg/d)
Number of subjects: 333

Group type: COMPARATOR
Intervention: MP (melphalan plus prednisone)
Number of subjects: 333
Study: 17923862

Group type: EXPERIMENTAL
Intervention: Lower glycaemic index diet (GI 52)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Higher glycaemic index diet (GI 64)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Laboratory investigation days (after lower and higher GI test breakfasts)
Number of subjects: 19
Study: 16614052

Group type: EXPERIMENTAL
Intervention: Musically enhanced bird song stimulus (2-h presentation from 0600 to 0800)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control stimulus (2-h presentation from 0600 to 0800)
Number of subjects: 11
Study: 12815566

Group type: EXPERIMENTAL
Intervention: Frequent telephone follow-up intervention by trained nurses
Number of subjects: 1518

Group type: COMPARATOR
Intervention: Usual follow-up (Control)
Number of subjects: 1518
Study: 10606935

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (n = 6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 12
Study: 8872060

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) 600 micrograms sublingually
Number of subjects: 12
Study: 1501967

Group type: EXPERIMENTAL
Intervention: Right-ear stimulus input
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: /Pa/-syllable presentations
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: /Ba/-syllable presentations
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: /Pa/-syllable presented to the left ear
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: EEG recorded from F3, Fz, and F4
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 12
Study: 6432417

Group type: EXPERIMENTAL
Intervention: Auranofin 6 mg/day
Number of subjects: 46

Group type: COMPARATOR
Intervention: D-penicillamine 500 mg/day
Number of subjects: 46
Study: 31107311

Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parenteral nutrition
Number of subjects: 0
Study: 27143319

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN) plus optimal medical therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Optimal medical therapy (control group)
Number of subjects: 60
Study: 25525065

Group type: EXPERIMENTAL
Intervention: Greek traditional dancing programme (Group A)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sedentary control group (Group B)
Number of subjects: 31
Study: 23726630

Group type: EXPERIMENTAL
Intervention: Cyclosporine mycophenolate mofetil (CM)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Tacrolimus/mycophenolate mofetil (TM)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Tacrolimus/mycophenolate mofetil with conversion to everolimus (TErl)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Not randomized (NR)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: BK viremia
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Patients with PAN
Number of subjects: 105
Study: 21362715

Group type: EXPERIMENTAL
Intervention: Intervention condition (adding or removing air to maintain cuff pressure)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control condition (usual care)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intervention condition (adding air to cuff)
Number of subjects: 32
Study: 19683087

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted H5N1 vaccine
Number of subjects: 1206
Study: 17302879

Group type: EXPERIMENTAL
Intervention: DHEA 50-mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 14759617

Group type: EXPERIMENTAL
Intervention: NuvaRing with a single dose of antimycotic
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: NuvaRing with multiple doses of antimycotic vaginal suppository
Number of subjects: 26

Group type: COMPARATOR
Intervention: NuvaRing with antimycotic vaginal cream
Number of subjects: 26

Group type: COMPARATOR
Intervention: NuvaRing alone
Number of subjects: 26
Study: 11802289

Group type: EXPERIMENTAL
Intervention: Fexofenadine 120 mg
Number of subjects: 176

Group type: COMPARATOR
Intervention: Cetirizine 10 mg
Number of subjects: 176
Study: 9778666

Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 18
Study: 7881139

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 416

Group type: COMPARATOR
Intervention: Chlorhexidine gluconate scrub
Number of subjects: 416
Study: 3130256

Group type: EXPERIMENTAL
Intervention: Sodium valproate (VPA) 500 mg t.i.d. for 5 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sodium valproate (VPA) in epileptic patients on established monotherapy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (age-matched controls)
Number of subjects: 8
Study: 30948271

Group type: EXPERIMENTAL
Intervention: Combined alcohol and sex exposure
Number of subjects: 338

Group type: COMPARATOR
Intervention: Sex only exposure
Number of subjects: 338

Group type: COMPARATOR
Intervention: Alcohol only exposure
Number of subjects: 338

Group type: COMPARATOR
Intervention: No risk exposure
Number of subjects: 338
Study: 28342967

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids and vitamin E co-supplementation (1000 mg omega-3 from flaxseed oil plus 400 IU vitamin E)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids and vitamin E co-supplementation
Number of subjects: 60
Study: 26556955

Group type: EXPERIMENTAL
Intervention: Morphine and ropivacaine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Morphine alone
Number of subjects: 36
Study: 23237175

Group type: EXPERIMENTAL
Intervention: Intervention group (training of opinion leaders to disseminate stigma reduction messages)
Number of subjects: 1760
Study: 21218039

Group type: EXPERIMENTAL
Intervention: Type D individuals
Number of subjects: 1357

Group type: EXPERIMENTAL
Intervention: Korean DS14
Number of subjects: 1357

Group type: EXPERIMENTAL
Intervention: General population and cardiovascular patients with Type D personality
Number of subjects: 1357
Study: 18716734

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient food supplement (MMFS)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (day scholars who did not eat at the school)
Number of subjects: 123
Study: 17140526

Group type: EXPERIMENTAL
Intervention: Vector system (piezo-driven ultrasonic device)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional method (dental bur)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 31
Study: 12816748

Group type: EXPERIMENTAL
Intervention: Aerobic training (6 sessions/week at 70-80% of maximum heart rate for 30-60 min/session)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 39
Study: 14635300

Group type: EXPERIMENTAL
Intervention: Mensendieck system (MS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Body awareness therapy (BAT)
Number of subjects: 20
Study: 9349677

Group type: EXPERIMENTAL
Intervention: Rhythmic Auditory Stimulation (RAS) during gait training
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional physical therapy gait program (Control)
Number of subjects: 10
Study: 8211671

Group type: EXPERIMENTAL
Intervention: External irradiation with a dose per fraction of 2 Gy
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: External irradiation with a dose per fraction of 3 Gy
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: External irradiation with a dose per fraction of 4 Gy
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: External irradiation with a dose per fraction of 5.4 Gy
Number of subjects: 203
Study: 2869723

Group type: EXPERIMENTAL
Intervention: 10 mg dezocine
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 5 mg dezocine
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 1 mg butorphanol
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 29856817

Group type: EXPERIMENTAL
Intervention: Dalteparin, 5000 IU daily
Number of subjects: 708

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH), 5000 IU twice daily
Number of subjects: 708
Study: 26947602

Group type: EXPERIMENTAL
Intervention: Tadalafil 5mg once a day
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Tadalafil 20mg on demand
Number of subjects: 423

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic surgery (yes)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic surgery (no)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Quality of nerve sparing (NSS <2.5)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Quality of nerve sparing (NSS ≥2.5)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: High presurgery sexual desire (IIEF item 12: ≥3.5)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Low presurgery sexual desire (IIEF item 12: <3.5)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: High confidence to get and maintain an erection (IIEF item 15: ≥3.5)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Low confidence to get and maintain an erection (IIEF item 15: <3.5)
Number of subjects: 423
Study: 24231654

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 8.75 mg lozenge
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo lozenge
Number of subjects: 204
Study: 23257488

Group type: EXPERIMENTAL
Intervention: Submerged healing
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-submerged healing
Number of subjects: 48
Study: 20629630

Group type: EXPERIMENTAL
Intervention: Genistein aglycone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study: 18727753

Group type: EXPERIMENTAL
Intervention: Peer-support groups
Number of subjects: 660

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 660
Study: 15688086

Group type: EXPERIMENTAL
Intervention: 100 microg ghrelin (i.v. bolus injection)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 9
Study: 12441831

Group type: EXPERIMENTAL
Intervention: Alfentanil and ketamine infusions targeting plasma concentrations of 75 ng/ml for alfentanil and 150 ng/ml for ketamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo equivalent
Number of subjects: 0
Study: 10028212

Group type: EXPERIMENTAL
Intervention: Child psychotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Academic tutoring (Control)
Number of subjects: 0
Study: 7750916

Group type: EXPERIMENTAL
Intervention: GH at a dose of 0.5 IU/kg/week
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: GH at a dose of 1.0 IU/kg/week
Number of subjects: 63
Study: 2324409

Group type: EXPERIMENTAL
Intervention: Fenoterol (400 micrograms)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 40840

Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 60
Study: 31675621

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 50-200 mg/day
Number of subjects: 1402

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1402
Study: 27739182

Group type: EXPERIMENTAL
Intervention: Continue donepezil for 52 weeks
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Start memantine
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Donepezil-memantine combined
Number of subjects: 295

Group type: COMPARATOR
Intervention: Discontinue donepezil
Number of subjects: 295
Study: 25530454

Group type: EXPERIMENTAL
Intervention: Caffeinated energy drink (3 mg of caffeine per kg of body mass)
Number of subjects: 16
Study: 23895631

Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei ssp paracasei F19 (LF19) 10^8 CFU
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo (cereals without LF19)
Number of subjects: 171
Study: 21836149

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 3276

Group type: COMPARATOR
Intervention: Control (no cinacalcet)
Number of subjects: 3276
Study: 19153263

Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (physician visits)
Number of subjects: 150
Study: 16990605

Group type: EXPERIMENTAL
Intervention: FEIBA (factor VIII inhibitor‐bypassing activity)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: NovoSeven (recombinant factor VIIa)
Number of subjects: 48
Study: 15140480

Group type: EXPERIMENTAL
Intervention: High-resolution ultrasound
Number of subjects: 18
Study: 12684362

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: 0.3 microg/kg rhvCNTF
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: 1.0 microg/kg rhvCNTF
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: 2.0 microg/kg rhvCNTF
Number of subjects: 173